Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISOThrive microFood
- Development stage
- Unknown
- Lead developer
- IsoThrive
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
ISOThrive microFood is a prebiotic supplement developed by ISOThrive Inc. to address gut microbiome dysbiosis. Its active ingredient is maltosyl-isomaltooligosaccharides (MIMO), a proprietary digestion-resistant carbohydrate that acts as a non-digestible soluble fiber. Unlike traditional drugs, it functions by selectively nourishing beneficial bacteria in the gut, specifically aiming to restore gram-positive bacterial predominance at the lower esophageal sphincter. It is being investigated under the therapeutic designation ISOT-101 for gastrointestinal conditions such as gastroesophageal reflux disease (GERD), irritable bowel syndrome with constipation (IBS-C), and functional dyspepsia. It is also commercially available as a dietary supplement for general digestive health.
- Brand names
- ISOThrive microFoodISOThrive microFood Nectar
- Other names
- MIMOmaltosyl-isomaltooligosaccharides
Beyond the preview
Go deeper on ISOThrive microFood.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISOThrive microFood.